Cogent Biosciences, Inc. COGT

COGT Company Overview

Cogent Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases, primarily in oncology and rare immune disorders. The company’s core focus is on diseases driven by alterations in the KIT receptor tyrosine kinase, including systemic mastocytosis and gastrointestinal stromal tumors (GIST). Cogent operates within the biotechnology and biopharmaceutical industries, with its primary value drivers centered on proprietary small-molecule therapeutics and clinical-stage drug development programs.

The company’s lead product candidate is bezuclastinib (CGT9486), an orally administered, selective KIT D816V inhibitor designed to target mutations associated with systemic mastocytosis while minimizing off-target toxicities observed with earlier KIT inhibitors. Cogent has positioned itself as a targeted precision medicine company emphasizing highly selective kinase inhibition and differentiated safety profiles. The company traces its origins to the merger between Unum Therapeutics and private biotechnology firm Cogent Biosciences in 2020, after which the combined company adopted the Cogent Biosciences name and shifted strategic focus toward KIT-driven diseases.